Hrain's CD19 CAR-T Therapy Approved as China's Fourth for Lymphoma

On 30 July China's National Medical Products Administration (NMPA) approved local company Hrain Biotechnology's Hengkailai for relapsed/refractory large B-cell lymphoma, making it the fourth CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy cleared in China. The approval was based on Phase II trial data showing 74.1% objective response rate (ORR) and 49.4% complete response rate (CRR) in 81 patients, with median duration of response (mDOR) reaching 339 days.

Safety data indicated 95.1% cytokine release syndrome incidence (3.7% grade ≥3) and 8.6% immune effector cell-associated neurotoxicity syndrome (no grade ≥3 cases). Hrain's product joins three existing CD19 CAR-T therapies from Fosun Kairos, JW Therapeutics and Juventas in China's competitive lymphoma treatment market, among a total of seven approved CAR-T therapies in the country, according to PharmCube's NextBiopharm® database. Click here to request a free trial for NextBiopharm®.

Subscribe to our newsletter
A weekly newsletter curated for industry professionals. Join thousands of fellow subscribers for free
Subscribe for Free
Daily News
InnoGen Debuts on HKEX With Record 5364 Times Oversubscription
2025-08-16
Qihan Bio Greenlit to Put Off-the-Shelf CAR-T into US Trials
2025-08-16
RemeGen's Telitacicept Succeeds in Sjögren's Syndrome Phase III Trial
2025-08-16
TYK's Asandeutertinib Aces ORR Against Brain Metastases from NSCLC
2025-08-16
Canbridge Soars 34% After USD 12.8m Strategic Investment by Baheal
2025-08-15
Latest Report
From Reliance to Defiance: A Decade-Long Panorama of China's Innovative Drug Transactions
Details